Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

Eli Lilly just gave investors several reasons to cheer.The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as glucagon-like peptide-1 (GLP-1) receptor agonists, blockbuster drugs such as Ozempic, Wegovy, Mounjaro, Zepbound, and others are completely redefining how care is provided to patients with diabetes or in need of weight management.While Danish-based pharmaceutical company Novo Nordisk (NVO -1.90%) leads the GLP-1 market (thanks in large ...

When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it has been highly effective in doing that. The success of Ozempic and Wegovy has helped the company behind the products, Novo Nordisk (NVO -0.04%), become one of the most valuable healthcare stocks in the world. But in an increasingly co ...

Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake. A long streak doesn't necessarily make a dividend stock a good long-term buy. After all, those increases may only be modest, for the sake of keeping the streak going. And if a company increases its dividend by just one or two percentage points, that's not even going to offset inflation.What Eli Lilly (LLY -0.05%) is doing is far more impressive. The company has been increasing its di ...

China is the fourth major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024INDIANAPOLIS, Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's ...

Lilly just gave investors more reasons to cheer the company on.Pharmaceutical giant Eli Lilly (LLY -0.10%) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster diabetes and obesity care medications, Mounjaro and Zepbound.The excitement surrounding the weight loss market has fueled a stock-buying frenzy, propelling Lilly to a market capitalization of roughly $720 billion -- making it the most valuable pharmaceu ...

The international pharmaceutical giant Eli Lilly (NYSE: LLY ) has shown tremendous growth in the last few years. The growth happened thanks to its robust product portfolio, strategic acquisitions, and innovation-led initiatives. The company, which specializes in solving the world's most severe healthcare issues, isComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but ...

Core Insights - The collaboration between EVA Pharma and Eli Lilly aims to provide affordable insulin to one million people with diabetes in low- to middle-income countries by 2030 [1][5] - The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking the first regulatory approval for EVA Pharma's insulin products [2][3] - Lilly has supplied active pharmaceutical ingredients at reduced prices and provided technology transfer to enable local manufacturing of insulin [2][3] Company Developments - EVA Pharma has established a new biologics manufacturing facility and completed insulin formulations and stability testing [3] - The company is also seeking WHO pre-qualification for its human insulin injection to ensure high-quality standards [4] - Lilly and EVA Pharma have expanded their collaboration to include the manufacturing of treatments for immunological diseases across 56 countries [6] Strategic Goals - The collaboration is part of Lilly's 30x30 initiative, which aims to improve healthcare access for 30 million people in resource-limited settings by 2030 [5] - EVA Pharma's CEO emphasized the importance of localizing essential medicines to drive equitable healthcare access [5] - The partnership is expected to impact over a million lives annually across 56 countries, demonstrating the potential of collaborative efforts in healthcare [5]

Company Overview - Eli Lilly (LLY) announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approving its IL-23p19 antibody Omvoh (mirikizumab) for expanded use in Crohn's disease (CD) [1] - Omvoh is currently approved in more than 44 countries, including the United States and Europe, to treat adults with moderate-to-severely active ulcerative colitis (UC) [3] Clinical Data and Regulatory Status - The positive recommendation for Omvoh is based on data from the phase III VIVID-1 study, which demonstrated effectiveness in CD patients with or without prior biologic failure [2] - A similar regulatory filing for Omvoh is under review with the FDA, with a final decision expected in the first half of 2025 [2] Market Performance - Year to date, Eli Lilly's shares have risen 35.4% compared to the industry's growth of 6.3% [4] Competitive Landscape - The targeted inflammatory bowel disease (IBD) market is highly competitive, with key players including AbbVie (ABBV) and Johnson & Johnson (JNJ) [6][7] - AbbVie's key immunology products, Skyrizi and Rinvoq, have generated nearly $10 billion in combined sales in the first nine months of 2024 [8] - J&J's Stelara and Tremfya have also performed well, with Stelara contributing over $8 billion in sales and Tremfya recording $2.7 billion in the same period [10][11] Industry Trends - There has been a surge in the prevalence of IBD disorders due to genetic, environmental, and lifestyle factors, driving demand for treatments [6] - Several major drugmakers, including Merck, Pfizer, Novartis, Sanofi, Gilead, and Amgen, are developing new medicines with novel mechanisms of action for IBD [12]

SAN FRANCISCO and SUZHOU, China, Dec. 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and Eli Lilly and Company (NYSE: LLY) today jointly announced a Distribution and Promotion Agreement in Mainland China regarding Lilly's non-covalent (reversible) Bruton's t ...